LifeArc's Chief Scientific Officer calls for UK science to continue to be a contributor to the Horizon Europe programme.
The new antibody offers hope of an effective new treatment option for millions of people.
We at LifeArc are deeply saddened by the passing of our monarch, Her Majesty Queen Elizabeth II.…
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science
Our technology transfer team played a crucial role in the formation of Constructive Bio, a new Medical…
Four grants awarded to projects that aim to translate research discoveries into benefits for children affected by rare diseases
New £4.25 million grant kick starts UK-wide collaborative research effort to end motor neuron disease
Collaboration will work together to find solutions to MND within years, not decades
New £30 million translational partnership will accelerate development of new treatments for people with dementia
Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe asthma